Anyone used 3bp (3-bromopyruvate)?

5132 Posts | Page(s): Prev 12...511 512 513 514  Next 

RE: Anyone used 3bp (3-bromopyruvate)?

by JohnnyP on Mon Sep 16, 2019 12:23 PM

Quote | Reply

Link to Steven's thread on another forum:

https://tinyurl.com/Syro-plus-Metformin-thread

RE: Anyone used 3bp (3-bromopyruvate)?

by JohnnyP on Mon Sep 16, 2019 12:38 PM

Quote | Reply

Table 1 of US Patent 8,993,587 B3 shows the cancer types that have been tested with the syro/metformin.

Nearly all types tested show response, but a few did not.  MD-231 (triple negative) breast cancer is one of the non responders.

I'm pretty sure my wife's is ER+.

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Wed Sep 18, 2019 02:06 AM

Quote | Reply

On Sep 16, 2019 12:38 PM JohnnyP wrote:

Table 1 of US Patent 8,993,587 B3 shows the cancer types that have been tested with the syro/metformin.

Nearly all types tested show response, but a few did not.  MD-231 (triple negative) breast cancer is one of the non responders.

I'm pretty sure my wife's is ER+.

critic, thank you very much for the correction. It has been difficult trying to make it through the translations. D directed me to the Glab website in America. They have listed a large number of cancer indications that they they intend at some time to clinically test with KAT (which is in fact 3-BP). I am not entirely sure whether or not Korean trials will also be brought forward. There is of course Cage Pharma, that you also alerted the therad about.

   

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Fri Sep 20, 2019 07:51 PM

Quote | Reply

On Jul 14, 2019 1:38 AM Jcancom wrote:

critic, the Calitheria and Nektar drugs are exciting! We are approaching the point where powerful FDA approved pharmaceuticals could be available to amplify other metabolic strategies. I am considering what might happen if CB-839 were to be combined with other metabolics. Glutamine, glucose, OXPHOS these are important cancer targets. What happens when all of them could be selectively turned off in cancer cells?

Iovance Bio's TIL product will likely (assuming all goes to plan) be approved before NKTR-214 [1]. The company is working on a number of ways to improve efficacy. The first is to use PD1 positive TIL as the expression of this identifies the neoantigen-specific T-cells [2]. Earlier data from the U.S. NCI showed an improved response rate when compared to non-PD1 positive ('bulk') TIL [3]. They are looking at using different cytokines/agonistic antibody cocktails to enhance the expansion and effector functions [4-6]. Along with ways to attenuate cell differentiation [7], increase memory subsets [8,9] and 'silence' certain checkpoints [10].
I hope they test it with 214 (instead of high dose IL-2) [11,12] and/or CB-839 [13].
When it comes to CB-839 then it could be approved in the next few years. We know it has activity in certain types such as TNBC and could be combined with the R-KD and other treatments [14]. With OXPHOSi (IM156 [15] & ICAS [16]) all three should synergise together.
Refs:
10 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(18)30172-2

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Fri Sep 20, 2019 07:57 PM

Quote | Reply

Dracen Pharma's lead asset DRP-104, a glutamine antagonist should be in the clinic soon https://www.dracenpharma.com

RE: Anyone used 3bp (3-bromopyruvate)?

by JohnnyP on Sat Sep 21, 2019 02:59 PM

Quote | Reply

J:

Are there any on Daniel's forum taking syrosingopine with metformin?  I made a presentation to our oncologist last week, showing her the patent, the 17 page article, where to buy on alibaba, etc.  I told her it's in powder form and the dose will be very small, just milligrams, so I also ordered a good analytical scale.  I expected her to say don't try it, but instead said "Be very careful." 

SteveK is getting by with a very low cost scale with 1mg resolution, but I wanted something better.  This is the best deal I have found on a 0.1mg scale: https://tinyurl.com/noname-analytical-scale

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Sun Sep 29, 2019 08:28 PM

Quote | Reply

A pivotal trial of TYME-88 for third-line treatment of patients with metastatic pancreatic cancer is open [1].

Also, some updated data on Telaglenastat (CB-839) [2].

Refs:

1 https://clinicaltrials.gov/ct2/show/NCT03512756

2 http://www.calithera.com/wp-content/uploads/2019/09/ESMO2019

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Sun Sep 29, 2019 08:30 PM

Quote | Reply

On Sep 16, 2019 12:23 PM JohnnyP wrote:

Link to Steven's thread on another forum:

https://tinyurl.com/Syro-plus-Metformin-thread "" target="_blank" rel="nofollow">https://tinyurl.com/Syro-plus-Metformin-thread " target="_blank" rel="nofollow">https://tinyurl.com/Syro-plus-Metformin-thread

Here is another trial that may be of use to your wife https://clinicaltrials.gov/ct2/show/NCT04102436

RE: Anyone used 3bp (3-bromopyruvate)?

by JohnnyP on Mon Sep 30, 2019 02:30 PM

Quote | Reply

alibaba just informed me the syrosingopine ship date has changed, from 10/1 to 10/18.

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Fri Oct 04, 2019 12:37 AM

Quote | Reply

JohhnyP, sorry for my absence from the thread. D's forum has been quite active of late, since he posted a comprehensive list of treatments. Such a list should help people out a great deal as cancer can be so overwhlemingly too much information when people initially receive a diagnosis. People want something to get started with right away and often they get sidetracked with a great deal of research without much clinical followthrough. D's list could help people feel comfortable earlier. Cancer treatments truly are everywhere.

The big interest with D seems to be with Feb, more than syro.This might relate to the price mentioned in the low thousands range from Switzerland, though your mention of Chinese suppliers is a new one to me. We have seen how effective  OXPHOS-glycos dual combos can work in the past, and met+syro is within this treatment universe.

I am somewhat disappointed that I have not heard of formulations for Feb and syro etc.. I think we might be drifting more towards such formulations for metabolics because they offer such a large enhancement in treatment power.

While I have pulled back lately from posting, the excitement is clearly building in metabolics. I had been unsure whether even one 3-BP clinical trial would make forward motion, though now there might be as many as 3 3-BP clinical trials in preparation. Once the process begins to unfold perhaps even more formulations could emerge. I even start to wonder whether we might yet see 3-BrOP join in. Perhaps a company could buy the intellectual property and then formulate it. It has been dormant for so long that I start to wonder; how long do these patents last for? On a newly created 3-BP site for the clinical application they mentioned that 3-BP would stay on patent until ~2030. I am not sure whether that is truly fair. My thinking is that there should be an FDA roll-forward of patent rights if a drug were to be somewhat moving through trials especially for companies developing drugs such as 3-BP which have found it difficult to attract major pharma interest for 20 years. Why don't they start the clock when the drug is approved and not when it is filed?  

5132 Posts | Page(s): Prev 12...511 512 513 514  Next 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.